Paul Tudor Jones’s 10x Genomics TXG Stock Holding History

Paul Tudor Jones’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-2,500	Closed	-$490K	–	2811
2021 Q2	$490K	Buy	+2,500	New	+$452K	0.01%	1169

Other funds holding TXG

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Paul Tudor Jones's TXG Position: Q4 2025 in Review

Paul Tudor Jones sold out of 10x Genomics (TXG) in Q4 2025, closing a stake of 76,909 shares — an estimated $899K sold.

Paul Tudor Jones first reported a position in TXG in Q3 2019 and held it in 17 quarters. The position peaked at $9.55M in Q2 2023. 322 funds tracked by Wall St. Rank hold TXG as of Q4 2025.

Paul Tudor Jones reported no remaining 10x Genomics position as of Q4 2025 after selling out during the quarter.
Paul Tudor Jones sold 76,909 10x Genomics shares in Q4 2025, an estimated $899K.
Paul Tudor Jones first reported a position in 10x Genomics in Q3 2019 and held it in 17 quarters.
Paul Tudor Jones's 10x Genomics position peaked at $9.55M in Q2 2023.
322 funds tracked by Wall St. Rank held 10x Genomics as of Q4 2025.

Based on Tudor Investment Corp's 13F filing for Q4 2025, filed 17 Feb 2026.